Author: Aisha T. Terry, MD, MPH, FACEP, Associate Professor of Emergency Medicine and Health Policy, George Washington University School of Medicine and Hospital, American College of Emergency Physicians, Board of Directors Member
The COVID-19 pandemic is rapidly evolving, as are the associated health care challenges. Despite the widespread global incidence and increasing number of cases, the epidemiology and clinical presentation of COVID-19 in pediatric patients is not well understood. The majority of children seen for emergency medical problems in the US are seen in general emergency departments, not pediatric-specific institutions, and this will likely continue with the current pandemic. Note that the information in this section is based on current evidence and evolving information. It is intended to assist in the evaluation and management of pediatric patients (not neonates) with suspected or confirmed COVID-19.
A significant proportion of pediatric cases appear to be associated with household contact. The incubation period averages 5 to 6 days, with a range of 2 to 14 days.1 Pediatric patients appear to have the lowest rate of infection of all age groups, although the apparently low incidence may be due to a significant proportion of asymptomatic and mild cases in children that are not recognized and tested. Current reports suggest very low rates of hospitalization and critical disease (including ICU admission) in pediatric patients.2,3 Of those patients considered to have critical disease, the majority were <1 year old.4 Similarly, the mortality rate in pediatric patients appears to be very low. The CDC (MMWR) reported no pediatric deaths related to COVID-19 in the US as of March 16, 2020.1 Two epidemiological studies from China, the first with 965 pediatric patients (a subset of a larger study cohort) and the second with 2,143 pediatric patients (731 laboratory-confirmed cases; 1,412 suspected cases), reported only 1 death, respectively, in each cohort of patients.3,4 There is very limited data on pediatric patients with chronic disease states and comorbid conditions. Patients with chronic disease states and comorbid conditions, particularly those with pulmonary or respiratory diseases and those considered immunosuppressed, whether congenital or acquired (including patients on chronic steroids), must be considered high risk for developing severe or critical disease.
Person-to-person spread via respiratory droplets is thought to be the predominant means of transmission, although some emerging evidence suggests a potentially increasing role of spread via aerosols. It is presumed that transmission can also occur via contaminated fomites. At least one study has demonstrated that SARS-CoV-2 (the virus that causes COVID-19) may remain viable in aerosols for up to 3 hours, on cardboard for up to 24 hours, and on plastic and stainless steel for as long as 3 days.5 It is unclear whether infection can be spread via other body fluids (eg, blood, stool). However, SARS-CoV-2 RNA has been detected in stool specimens, and in pediatric patients, it has been demonstrated to persist longer in stool than in the nasopharynx.6 More information is available from the CDC’s “Clinical Questions about COVID-19: Questions and Answers” section.
A significant proportion of pediatric patients appear to be asymptomatic. In two reports, the proportion of asymptomatic cases was 12.9% and 15.8%, respectively, in confirmed cases.4,7,11 The most common clinical characteristics in symptomatic pediatric patients appear to be fever and cough. Other clinical characteristics include pharyngeal erythema, diarrhea, fatigue, rhinorrhea, nasal congestion, vomiting, and fatigue. Tachypnea and hypoxia have been identified in more severe cases.7,8,9
Testing recommendations for pediatric patients are similar to those for adults but are rapidly evolving as the pandemic continues. More information is available from the CDC on “Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19)” and on the Florida Department of Health’s “Health Care Providers” web page.
No specific therapeutic drugs for COVID-19 are currently approved by the FDA. Initial management priorities should include infection control measures and supportive treatment as indicated. Although several potential therapeutic agents are currently being investigated, none are currently recommended by the CDC for treating pediatric patients with COVID-19. According to the NIH COVID 19 Guidelines, there are insufficient data to recommend for or against the use of specific antivirals or immunomodulatory agents for the treatment of COVID-19 in pediatric patients. More information regarding investigational therapeutics is provided in the CDC’s “Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19).” Additionally, information regarding specific clinical trials is available at the NIH’s clinicaltrials.gov website. Pediatric patients with asymptomatic or mild disease, who are not high-risk patients (eg, immunosuppressed) and for which admission is not clinically indicated, may not require transfer to a pediatric center. The decision to admit a patient to the hospital or continue observation at home must be made on a case-by-case basis. As a significant proportion of pediatric patients appear to have a mild disease course associated with COVID-19, it is likely that many will be candidates for outpatient management. Pediatric patients managed on an outpatient basis must be provided clear information and instructions regarding infection spread control, potential progression of signs and symptoms, and return precautions. Parents who care for pediatric patients being quarantined due to having a confirmed diagnosis of COVID-19, COVID-19 exposure, or awaiting COVID-19 test results should wear appropriate PPE to prevent transmission.